ABTECT Phase 3 Trial Hits 600-Patient Milestone, On Track For Full Enrollment By Early Q1 2025
Portfolio Pulse from Benzinga Newsdesk
The Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) has surpassed the 600-patient enrollment milestone and is on track to reach full enrollment by early Q1 2025. Baseline participant characteristics and trial trends are consistent with observations from the Phase 2b trial.
August 06, 2024 | 6:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ABVX's Phase 3 ABTECT Trial for obefazimod in ulcerative colitis has reached a significant milestone with 600 patients enrolled, and is on track for full enrollment by early Q1 2025. This progress aligns with positive trends observed in the Phase 2b trial.
The successful enrollment milestone and alignment with positive Phase 2b trial trends suggest a promising outlook for ABVX's obefazimod. This progress is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100